等待开盘 04-02 09:30:00 美东时间
-0.570
-1.75%
今日重点评级关注:瑞穗:维持RELMADA THERAPEUTICS"跑赢大市"评级,目标价从10美元升至19美元;奥本海默:维持Pelthos Therapeutics"跑赢大市"评级,目标价从60美元升至62美元
03-23 13:53
今日重点评级关注:RBC Capital:维持4D Molecular Therapeutics"跑赢大市"评级,目标价从32美元升至35美元;巴克莱:维持CytomX医疗"超配"评级,目标价从10美元升至16美元
03-20 15:53
U.S. RESEARCH ROUNDUP- Air Products, Chevron, Fedex March 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Air Products, Chevron and Fedex on Friday. HIGHLIGHTS * Air Products APD.N : JP Morgan raises to overweight fro
03-20 14:50
今日重点评级关注:韦德布什:维持Black Diamond Therapeutic"跑赢大市"评级,目标价从13美元升至14美元;花旗:维持Olema Pharmaceuticals"买入"评级,目标价从60美元升至62美元
03-18 10:48
Wall Street analysts changed outlook on top names: Morgan Stanley raised Lemonade's PT to $85, Mizuho cut Canadian Solar's PT to $19, Piper Sandler raised Tandem Diabetes' PT to $33, Stifel increased Ichor's PT to $55, Needham raised Semtech's PT to $105, HC Wainwright cut Eupraxia Pharma's PT to $11, Evercore ISI Group raised National Storage Affiliates Trust's PT to $41.
03-17 19:49
Needham analyst Joseph Stringer maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and raises the price target from $35 to $40.
03-17 19:13
–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease––Data support ongoing global Phase 3
03-05 06:07
NervGen Pharma Corp. has appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as Senior Vice President of Patient Advocacy and Clinical Affairs. Both bring extensive experience to support NervGen's lead therapeutic, NVG-291, which is advancing through clinical trials for spinal cord injury (SCI). Ruff, with over 30 years in regulatory affairs, will oversee the company's regulatory strategy, while McSherry will ensure p...
03-04 12:30
今日重点评级关注:花旗:维持Telix Pharmaceuticals"买入"评级,目标价从22美元升至22.5美元;摩根士丹利:维持Vir Biotechnology"超配"评级,目标价从20美元升至24美元
02-25 11:03
Wolfe Research analyst Rudy Li initiates coverage on Stoke Therapeutics (NASDAQ:STOK) with a Outperform rating and announces Price Target of $40.
02-24 20:22